home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc From 06/06/24

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

GLAXF - GSK plc: Long-Term Cash Cow

2024-05-28 03:05:58 ET Summary On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 million, up 46.6% from the previous quarter. The...

GLAXF - Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows

2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...

GLAXF - CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements

2024-05-23 16:47:14 ET Summary CureVac N.V. is developing an avian influenza [H5N1] vaccine with GSK plc; A phase 1 study is already underway to evaluate this vaccine. It is working on a seasonal influenza vaccine, but further optimization is needed to target influenza B; Dose-opt...

GLAXF - GSK Breathes New Life Into Asthma Treatment With Depemokimab

2024-05-22 11:19:16 ET Summary GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinic...

GLAXF - International Wide-Moat Stocks On Sale - The May 2024 Heat Map

2024-05-08 12:01:57 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investible candidates that may b...

GLAXF - GSK plc (GSK) Q1 2024 Earnings Call Transcript

2024-05-04 00:00:06 ET GSK plc (GSK) Q1 2024 Earnings Conference Call May 01, 2024 03:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chie...

GLAXF - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

GLAXF - Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...

GLAXF - GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve

2024-04-19 04:02:55 ET Summary GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate the effectiveness and efficiency of its pipelin...

Previous 10 Next 10